Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Preventing Progression in Decompensated Liver Cirrhosis
NCT05863364Recruiting
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifaximin in Liver cirrhosis (LC) (3 arms). Primary endpoint: Proportion of patients with progression of liver cirrhosis at 24 weeks. Started Aug 2023; status: recruiting.
02
Drugs
rifaximin
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT05863364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05863364.